Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
Phase 2
Completed
- Conditions
- CancerColorectal CancerOncologyCarcinomaColon CancerGastrointestinal CancerMetastasesMetastatic CancerMetastatic Colorectal CancerRectal Cancer
- Interventions
- First Posted Date
- 2008-09-15
- Last Posted Date
- 2015-09-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 144
- Registration Number
- NCT00752570
A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-08-22
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 322
- Registration Number
- NCT00739648
LEARN-6™: A Prospective, Observational Nursing Home Study
Completed
- Conditions
- AnemiaChronic Kidney Disease
- Interventions
- Other: Observations
- First Posted Date
- 2008-08-04
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 815
- Registration Number
- NCT00727571
Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
- First Posted Date
- 2008-07-24
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 50
- Registration Number
- NCT00721734
- Locations
- 🇺🇸
University of California- San Francisco, San Francisco, California, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of Maryland Medical Center, Baltimore, Maryland, United States
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer
Phase 1
Completed
- Conditions
- Gastric CancerEsophageal CancerEsophagogastric Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2008-07-21
- Last Posted Date
- 2013-12-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 130
- Registration Number
- NCT00719550
A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma
- First Posted Date
- 2008-05-29
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 12
- Registration Number
- NCT00686335
- Locations
- 🇫🇷
Hôpital Bichat, Paris, France
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
Phase 2
Completed
- Conditions
- Benign Giant Cell TumorsCancerGiant Cell TumorsGiant Cell Tumor of Bone
- Interventions
- First Posted Date
- 2008-05-20
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 535
- Registration Number
- NCT00680992
- Locations
- 🇬🇧
Research Site, Birmingham, United Kingdom
Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients
- First Posted Date
- 2008-05-14
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 151
- Registration Number
- NCT00677365
- Locations
- 🇺🇸
Childrens Hospital, Los Angeles, California, United States
🇺🇸Oklahoma CF Center, Oklahoma City, Oklahoma, United States
A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes Mellitus
Phase 2
Withdrawn
- Conditions
- Diabetes Mellitus
- Interventions
- Biological: AMG 108Biological: Placebo
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Amgen
- Registration Number
- NCT00661921
Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism
Phase 2
Completed
- Conditions
- Aldehyde Dehydrogenase-2 (ALDH2) Deficiency
- Interventions
- First Posted Date
- 2008-04-18
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 32
- Registration Number
- NCT00661141
- Locations
- 🇺🇸
Covance Honolulu CRU, Honolulu, Hawaii, United States
© Copyright 2025. All Rights Reserved by MedPath